24 related articles for article (PubMed ID: 38604128)
1. PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets.
Zhang S; Wang J; Liu Q; McDonald WH; Bomber ML; Layden HM; Ellis J; Borinstein SC; Hiebert SW; Stengel KR
Mol Cell; 2022 Dec; 82(23):4428-4442.e7. PubMed ID: 36395771
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
3. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
4. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.
Trinh DL; Scott DW; Morin RD; Mendez-Lago M; An J; Jones SJ; Mungall AJ; Zhao Y; Schein J; Steidl C; Connors JM; Gascoyne RD; Marra MA
Blood; 2013 May; 121(18):3666-74. PubMed ID: 23460611
[TBL] [Abstract][Full Text] [Related]
5. CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma.
Thieme E; Bruss N; Sun D; Dominguez EC; Coleman D; Liu T; Roleder C; Martinez M; Garcia-Mansfield K; Ball B; Pirrotte P; Wang L; Xia Z; Danilov AV
Mol Cancer; 2023 Mar; 22(1):64. PubMed ID: 36998071
[TBL] [Abstract][Full Text] [Related]
6. PAX3-FOXO1: Zooming in on an "undruggable" target.
Wachtel M; Schäfer BW
Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205
[TBL] [Abstract][Full Text] [Related]
7. The regulation of FOXO1 and its role in disease progression.
Xing YQ; Li A; Yang Y; Li XX; Zhang LN; Guo HC
Life Sci; 2018 Jan; 193():124-131. PubMed ID: 29158051
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide analysis of chromatin accessibility using ATAC-seq.
Shashikant T; Ettensohn CA
Methods Cell Biol; 2019; 151():219-235. PubMed ID: 30948010
[TBL] [Abstract][Full Text] [Related]
9. Super-enhancers and novel therapeutic targets in colorectal cancer.
Liu Q; Guo L; Lou Z; Xiang X; Shao J
Cell Death Dis; 2022 Mar; 13(3):228. PubMed ID: 35277481
[TBL] [Abstract][Full Text] [Related]
10. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
11. Mutant FOXO1 controls an oncogenic network via enhancer accessibility.
Layden HM; Ellis JD; Bomber ML; Bartlett LN; Hiebert SW; Stengel KR
Cell Genom; 2024 Apr; 4(4):100537. PubMed ID: 38604128
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
